title: Progress of vaccine and drug development for Ebola preparedness.
abstract: Since the first case of Ebola virus disease (EVD) in Guinea was reported in March 2014 by World Health Organization (WHO), the outbreak has continued through the year and the total number of 19,065 patients was reported as the confirmed or suspected in the EVD-affected countries. Among the cases, 7,388 patients were reported death by 19 December. Currently, available therapeutics to treat the infected patients or vaccines to prevent people from infection is not developed yet while viral diagnostic methods were already developed and firmly established in a lot of countries as a first step for the preparedness of Ebola outbreak. Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD. Several candidates of vaccines also were investigated their efficacy in animal models by National Institute of Health (NIH) and Department of Defense, and they are processing of clinical tests in West Africa aiming to finish the development by the 2015. Vaccine and therapeutic development is essential to stop the EVD outbreak in West Africa, also to protect the world from the risk which can be generated by potential spread of Ebola virus.
authors: Division of Arboviruses, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju, Korea.
authors: Woo Young
authors: 0000-0003-2507-7381
authors: WY
authors: Choi
authors: Division of High-risk Pathogen Research, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju, Korea.
authors: Kee-Jong
authors: 0000-0003-2054-7014
authors: KJ
authors: Hong
authors: Division of Bioterrorism Preparedness and Response, Korea Centers for Disease Control and Prevention, Cheongju, Korea.
authors: Joo Eun
authors: 0000-0002-6487-604X
authors: JE
authors: Hong
authors: Division of Arboviruses, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongju, Korea.
authors: Won-Ja
authors: 0000-0002-9519-0219
authors: WJ
authors: Lee
keywords: Drug development; Ebola hemorrhagic fever; Ebola virus; Vaccines
references: Nature. 2000 Nov 30;408(6812):605-9
references: 11117750
references: Virology. 1998 Jun 20;246(1):134-44
references: 9657001
references: Emerg Infect Dis. 2002 May;8(5):503-7
references: 11996686
references: Nature. 2014 Oct 2;514(7520):47-53
references: 25171469
references: Expert Rev Vaccines. 2011 Jan;10(1):63-77
references: 21162622
references: Nat Rev Microbiol. 2009 May;7(5):393-400
references: 19369954
references: Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5
references: 23071322
references: J Infect Dis. 1999 Feb;179 Suppl 1:S1-7
references: 9988155
references: Crit Care Clin. 2005 Oct;21(4):765-83, vii
references: 16168314
references: J Virol. 2003 Sep;77(18):9733-7
references: 12941881
references: Expert Opin Biol Ther. 2012 Jul;12(7):859-72
references: 22559078
references: Nature. 2003 Aug 7;424(6949):681-4
references: 12904795
references: PLoS Negl Trop Dis. 2010 Oct 05;4(10):null
references: 20957152
references: Expert Rev Vaccines. 2003 Dec;2(6):777-89
references: 14711361
references: J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81
references: 21987744
references: Bull World Health Organ. 1983;61(6):997-1003
references: 6370486
references: N Engl J Med. 2014 Oct 9;371(15):1418-25
references: 24738640
references: Front Microbiol. 2012 Feb 06;3:34
references: 22363323
references: Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8873-6
references: 24912183
references: J Bioterror Biodef. 2011 Sep 25;S1(4):null
references: 22288023